{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06059651",
            "orgStudyIdInfo": {
                "id": "PBRC 2023-026"
            },
            "organization": {
                "fullName": "Pennington Biomedical Research Center",
                "class": "OTHER"
            },
            "briefTitle": "The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology",
            "officialTitle": "The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "the-effects-of-metabolic-bariatric-surgery-on-lipid-metabolism-myeloid-derived-suppressor-cells-and-cancer-cell-biology"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-22",
            "studyFirstSubmitQcDate": "2023-09-22",
            "studyFirstPostDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Justin Brown",
                "investigatorTitle": "Director, Cancer Metabolism Program",
                "investigatorAffiliation": "Pennington Biomedical Research Center"
            },
            "leadSponsor": {
                "name": "Pennington Biomedical Research Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study aims to determine the relationship between lipid kinetics changes and blood immunosuppressive cells by metabolic surgery in two patient cohorts."
        },
        "conditionsModule": {
            "conditions": [
                "Obesity"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "description": "Cohort #1 (within-subject) will enroll up to 10 women with class III obesity who plan to undergo Roux-en-Y metabolic and bariatric surgery as a standard of obesity care. Subjects will complete study measures preoperatively and one year postoperatively.",
                    "interventionNames": [
                        "Procedure: Metabolic & Bariatric Surgery"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "description": "Cohort #2 (between-subject) will enroll up to 10 women with a history of class III obesity who underwent Roux-en-Y metabolic and bariatric surgery as a standard of obesity care approximately one year before enrollment. Subjects in this cohort will be matched on demographic and clinical variables to those in Cohort #1.",
                    "interventionNames": [
                        "Procedure: Metabolic & Bariatric Surgery"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Metabolic & Bariatric Surgery",
                    "description": "Roux-en-Y metabolic and bariatric surgery",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in insulin-inhibited adipose tissue lipolysis",
                    "timeFrame": "Baseline, week 52"
                },
                {
                    "measure": "Change in the number of circulating myeloid-derived suppressor cells",
                    "timeFrame": "Baseline, week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "For an eligible subject, all the following must be answered \"yes\":\n\n* Biological female sex\n* Age \\>=35 and \\<=60 years (including pre- and postmenopausal)\n* Self-reported white or black race\n* The study will enroll approximately 50% white and 50% black subjects\n* Body mass index \\>/=40 kg/m2\n* Have a diagnosis of hyperlipidemia (high triglycerides and LDL-cholesterol) or in treatment with any medication for hyperlipidemia at enrollment\n* Ability to provide written informed consent\n* Allow the collection and storage of biospecimens and data for future use\n* Not having yet started the pre-op liquid diet before the bariatric surgery\n\nFor an eligible subject, all the following must be answered \"no\":\n\n* Have type one or type two diabetes\n* Use of anti-inflammatory medications, such as glucocorticoids or non-steroidal anti-inflammatory medications, within the past 15 days\n* Use of medication approved for obesity management, including, but not limited to, phentermine-topiramate (Qsymia), orlistat (Xenical), naltrexone-bupropion (Contrave), liraglutide (Saxenda), and semaglutide (Wegovy)\n* History of cancer of any type\n* History of chronic conditions known to cause inflammation, such as tuberculosis, autoimmune disease, and human immunodeficiency virus\n* An acute history (within the past 60 days) or confirmed or suspected SARS-CoV-2 (COVID-19) infection\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 52 weeks\n* Currently participating in another study with competing outcomes\n* Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "genderBased": true,
            "minimumAge": "35 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ],
            "studyPopulation": "The study population will include women with class III obesity who plan to undergo or have completed treatment with metabolic and bariatric surgery.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Justin Brown, Ph.D.",
                    "role": "CONTACT",
                    "phone": "2257632715",
                    "email": "justin.brown@pbrc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Justin Brown, Ph.D.",
                    "affiliation": "Pennington Biomedical Research Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Pennington Biomedical Resarch Center",
                    "status": "RECRUITING",
                    "city": "Baton Rouge",
                    "state": "Louisiana",
                    "zip": "70808",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Justin Brown",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.45075,
                        "lon": -91.15455
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}